Atra stock zacks

What stocks are you targeting when you trade LABU and LABD? between the market closing price and calculated net asset value per share of the ETFs. New 52-Week Lows. Symbol, Name, Current Price, Chg, % Chg, 52-Week Low , 52-Week High, Today's Volume, Stock Type, Market Cap, MarketCapFull  12 Feb 2019 For this study we are going to focus on healthcare stocks. We then took over This can enable them to anticipate significant price movements.

Atara Biotherapeutics: 4Q Earnings Snapshot - The Hour SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $78.5 million in its fourth quarter. On a per-share basis, the South San Francisco, California Atara Biotherapeutics: 4Q Earnings Snapshot - Beaumont ... SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $78.5 million in its fourth quarter. On a per-share basis, the South San Francisco, California

5 Jan 2018 Understanding value helps you set a price when you're selling. After all, you don't want to ask too little and leave money on the table, or ask too 

Atara Biotherapeutics (NASDAQ:ATRA) Stock Rating Upgraded ... Zacks Investment Research upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting […] ATRA - Atara Biotherap News - Barchart.com Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Wall Street analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings per share of ($1.33) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.29) and the lowest is ($1.37).

Aug 28, 2019 · Investors need to pay close attention to Atara (ATRA) stock based on the movements in the options market lately. Investors need to pay close attention to Atara (ATRA) stock based on the movements in the options market lately. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of $1.35 per share to a Atara Biotherapeutics: 4Q Earnings Snapshot - seattlepi.com SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $78.5 million in its fourth quarter. On a per-share basis, the South San Francisco, California

Feb 27, 2020 · SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $78.5 million in its fourth quarter. On a per …

ATRA Dividend History & Description — Atara Biotherapeutics Inc. Atara Biotherapeutics is an off-the-shelf, allogeneic T-cell immunotherapy company that is developing treatments for patients with cancer, autoimmune and viral diseases. ATRS Antares Pharma Inc. — Stock Price and ... - StockTwits Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.

The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.30 per share. For the year, the company reported that its loss widened to $291 million, or $5.67 per share. Atara Biotherapeutics shares have decreased 32% since the beginning of the year. The stock has fallen 70% in the last 12 months.

Brokerage Recommendations - Zacks Investment Research

Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of … Atara Biotherapeutics Inc (NASDAQ:ATRA) Short Interest ... Atara Biotherapeutics Inc (NASDAQ:ATRA) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 9,820,000 shares, an increase of 5.4% from the February 13th total of 9,320,000 shares. Based on an average daily volume of 655,100 shares, the days-to-cover ratio is currently 15.0 days. […] Stock News - research.tdameritrade.com